M.H. Haugen et al. [29] determined by reverse-phase protein arrays (RPPA) a nine-protein signature score in tumor samples able to predict the response to neoadjuvant treatment with bevacizumab in combination with chemotherapy in HER2-negative BC. The gene discussed is ERBB2; the disease is breast cancer.